gantenerumab-graduate

Gantenerumab GRADUATE Trial

Overview

The GRADUATE program was a comprehensive Phase 3 clinical trial program evaluating gantenerumab, a fully human anti-[amyloid-beta](/proteins/amyloid-beta) (Aβ) monoclonal antibody, for the treatment of early [Alzheimer's disease](/diseases/alzheimers-disease). The program consisted of two identical Phase 3 trials—GRADUATE I (NCT03444870) and GRADUATE II (NCT03443973)—designed to evaluate whether gantenerumab could slow cognitive and functional decline in patients with mild cognitive impairment due to AD or mild AD dementia[@roche2023][@honig2023].

Gantenerumab represented a unique approach among anti-amyloid antibodies due to its ability to bind with high affinity to aggregated forms of Aβ, including [oligomers](/mechanisms/amyloid-oligomers-neurodegeneration), fibrils, and plaques[@bohrmann2012]. The GRADUATE program was notable for its ambitious scale, rigorous biomarker confirmation requirements, and use of high-dose subcutaneous administration[@salloway2022].

Despite achieving substantial [amyloid plaque](/proteins/amyloid-beta) reduction—a finding that validated the antibody's mechanism of action—the trials failed to meet their primary clinical endpoint of slowing cognitive decline[@roche2023]. This paradox has provided critical insights into the relationship between amyloid clearance and clinical benefit, informing the development of next-generation anti-amyloid therapies.

Trial Details

GRADUATE I and II ClinicalTrials.gov Identifiers

Gantenerumab GRADUATE Trial

Overview

The GRADUATE program was a comprehensive Phase 3 clinical trial program evaluating gantenerumab, a fully human anti-[amyloid-beta](/proteins/amyloid-beta) (Aβ) monoclonal antibody, for the treatment of early [Alzheimer's disease](/diseases/alzheimers-disease). The program consisted of two identical Phase 3 trials—GRADUATE I (NCT03444870) and GRADUATE II (NCT03443973)—designed to evaluate whether gantenerumab could slow cognitive and functional decline in patients with mild cognitive impairment due to AD or mild AD dementia[@roche2023][@honig2023].

Gantenerumab represented a unique approach among anti-amyloid antibodies due to its ability to bind with high affinity to aggregated forms of Aβ, including [oligomers](/mechanisms/amyloid-oligomers-neurodegeneration), fibrils, and plaques[@bohrmann2012]. The GRADUATE program was notable for its ambitious scale, rigorous biomarker confirmation requirements, and use of high-dose subcutaneous administration[@salloway2022].

Despite achieving substantial [amyloid plaque](/proteins/amyloid-beta) reduction—a finding that validated the antibody's mechanism of action—the trials failed to meet their primary clinical endpoint of slowing cognitive decline[@roche2023]. This paradox has provided critical insights into the relationship between amyloid clearance and clinical benefit, informing the development of next-generation anti-amyloid therapies.

Trial Details

GRADUATE I and II ClinicalTrials.gov Identifiers

| Attribute | GRADUATE I | GRADUATE II |
|-----------|------------|-------------|
| NCT Number | NCT03444870 | NCT03443973 |
| Phase | Phase 3 | Phase 3 |
| Status | Completed (Terminated) | Completed (Terminated) |
| Sponsor | Roche/Genentech | Roche/Genentech |
| Start Date | October 2018 | October 2018 |
| Completion | January 2023 | January 2023 |
| Enrollment | ~1,400 patients | ~1,400 patients |

Trial Design

The GRADUATE trials were randomized, double-blind, placebo-controlled, parallel-group Phase 3 studies conducted at over 250 sites globally[@roche2023]:

• Randomization: 1:1 ratio of gantenerumab to placebo
• Treatment Duration: 116 weeks (approximately 2.2 years)
• Administration: Subcutaneous injection every 2 weeks
• Dosing Strategy: Titration from 255 mg to 510 mg over 24 weeks

Patient Population

The trials enrolled patients meeting the following criteria[@salloway2022][@roche2023]:

Inclusion Criteria:

• Age 50-90 years
• Diagnosis of [mild cognitive impairment](/diseases/mild-cognitive-impairment) (MCI) due to AD or mild AD dementia
• Clinical Dementia Rating (CDR) global score of 0.5 or 1.0
• MMSE score of 22-30
• Confirmed amyloid pathology via PET scan or CSF analysis
• Stable background medications (cholinesterase inhibitors, memantine)

• History of stroke or significant cerebrovascular disease
• Active psychiatric illness
• Cancer within 5 years
• Contraindications for MRI
• Previous anti-amyloid immunotherapy
• Significant white matter hyperintensities

Mechanism of Action

Gantenerumab operates through three complementary mechanisms to clear [amyloid-beta](/proteins/amyloid-beta) from the brain[@bohrmann2012][@abbright2019]:

Fc-Mediated Microglial Phagocytosis

The primary clearance mechanism involves Fc gamma receptor-mediated phagocytosis. After gantenerumab binds to aggregated Aβ on plaque surfaces, the IgG1 Fc domain engages Fc gamma receptors on [microglia](/cell-types/microglia), triggering engulfment and degradation of the antibody-Aβ complexes. This mechanism leverages the brain's natural immune surveillance to remove pathological protein deposits[@bohrmann2012].

Direct Plaque Disruption

Gantenerumab binds to multiple Aβ species on plaque surfaces, potentially destabilizing the aggregated structure and facilitating disaggregation. The antibody's conformational epitope recognition allows it to target both fibrillar core regions and more diffuse plaque components[@abbright2019].

Peripheral Sink Effect

Like other anti-amyloid antibodies, gantenerumab may create a peripheral sink by binding plasma Aβ, promoting efflux from the brain. This mechanism involves the antibody binding circulating Aβ in peripheral blood, establishing a concentration gradient that drives Aβ efflux from the central nervous system[@delrieu2017].

Epitope Specificity

Gantenerumab binds to a conformational epitope present on Aβ aggregates, with preference for N-terminal regions of fibrillar Aβ. This specificity distinguishes it from other anti-amyloid antibodies:

• Solanezumab: Prefers monomeric Aβ
• Crenezumab: Binds both oligomers and plaques
• Lecanemab: Prefers Aβ protofibrils
• Donanemab: Targets pyroglutamate Aβ plaques

Primary and Secondary Endpoints

Primary Endpoint

• Measure: Change from baseline in CDR-SB (Clinical Dementia Rating Sum of Boxes) at Week 116
• Rationale: CDR-SB is a validated global measure of cognition and function, widely accepted as the gold standard for AD clinical trials[@potkin1999]

Secondary Endpoints

| Endpoint | Instrument | Purpose |
|----------|------------|---------|
| Cognition | ADAS-Cog13 | Memory, language, praxis |
| Daily Function | ADCS-MCI-ADL | Activities of daily living |
| Global Change | CIBIC-Plus | Clinician's impression |
| Biomarker | Amyloid PET | Target engagement |
| Biomarker | CSF p-tau/tau | Downstream effects |
| Brain Structure | MRI volumetry | Brain atrophy rate |

Results

Primary Clinical Outcome

The GRADUATE trials did not meet their primary endpoint[@roche2023][@honig2023]:

| Measure | GRADUATE I | GRADUATE II |
|---------|-----------|-------------|
| CDR-SB treatment difference | -0.31 points | -0.19 points |
| Relative reduction vs placebo | 8% | 6% |
| Statistical significance | Not significant (p=0.22) | Not significant (p=0.40) |

For context, [lecanemab](/therapeutics/lecanemab) achieved a 27% relative reduction in CDR-SB decline (p<0.001) in the CLARITY AD trial, and [donanemab](/therapeutics/donanemab) achieved a 35% reduction (p<0.001) in TRAILBLAZER-ALZ 2[@vanDyck2023][@loyle2023].

Biomarker Results

Despite failing to meet the primary clinical endpoint, gantenerumab produced substantial biomarker changes that validated its mechanism of action[@salloway2022][@abbright2019]:

Amyloid Plaque Reduction (Amyloid PET)

| Trial | Centiloid Reduction (Active) | Difference from Placebo |
|-------|------------------------------|-------------------------|
| GRADUATE I | -75.73 | -66.44 |
| GRADUATE II | -65.96 | -56.46 |

These reductions, while substantial, were lower than those achieved by lecanemab (~80 centiloids) and donanemab (~70 centiloids)[@vanDyck2023][@loyle2023].

Amyloid Clearance to Negative Status

Only 28% of gantenerumab-treated participants achieved amyloid-negative PET status at endpoint, compared to approximately:

• 68% for lecanemab in CLARITY AD
• 80% for donanemab in TRAILBLAZER-ALZ 2

CSF Biomarker Effects

Gantenerumab demonstrated downstream effects on [tau](/proteins/tau) pathology and synaptic dysfunction[@klein2019]:

• CSF p-tau181: Significant reduction vs placebo
• CSF total tau: Significant reduction vs placebo
• CSF neurogranin: Reduction indicating synaptic benefit

Safety Profile

The safety profile was generally consistent with other anti-amyloid antibodies, with ARIA being the primary safety concern[@salloway2022]:

| Adverse Event | Gantenerumab | Placebo |
|--------------|--------------|---------|
| ARIA-E (edema) | 24.9% | 2.5% |
| Symptomatic ARIA-E | 5.0% | 0.4% |
| ARIA-H (hemorrhage) | Associated with ARIA-E | - |
| Injection site reactions | 24.4% | 18.8% |

Most ARIA events were mild to moderate and resolved without sequelae. The rate of ARIA-E was higher than observed with lecanemab (12.6%) but comparable to donanemab (~24%)[@salloway2022].

ARIA Management

The GRADUATE trials implemented rigorous ARIA monitoring protocols[@salloway2022][@masterman2023]:

• Baseline MRI before randomization
• MRI at Week 24, 52, and 80
• Dose pause and possible reduction for ARIA
• Symptom-driven MRI for any neurological changes

Clinical Significance and Lessons Learned

The gantenerumab GRADUATE program, despite its negative results, provided critical insights for the field of Alzheimer's disease drug development[@isselbacher2022][@fila2023]:

1. Amyloid Clearance Threshold

The relationship between amyloid reduction and clinical benefit may require near-complete clearance. The 28% amyloid-negative rate compared to 68-80% for newer antibodies suggests that incomplete target engagement may limit efficacy[@honig2023].

2. Dose and Brain Penetration

• Subcutaneous administration allowed higher doses but may have limited brain penetration
• The 510 mg biweekly dose may have been suboptimal for achieving complete amyloid clearance
• Earlier, more aggressive dosing might have produced different results
• Brain penetration remains a key challenge for anti-amyloid antibodies[@delrieu2017]

3. Downstream Pathology

Even substantial amyloid clearance may be insufficient if downstream [tau](/proteins/tau) pathology is too advanced. The GRADUATE results support the hypothesis that amyloid-targeting therapies may need to be combined with tau-targeting approaches for maximum clinical benefit[@musiek2023][@reim2023].

4. Patient Selection

Biomarker-confirmed amyloid pathology alone may not be sufficient. Future trials may need to incorporate:

• Tau biomarker status
• Genetic risk factors (APOE4 carrier status)
• More sensitive cognitive measures
• Earlier intervention in the disease process[@scheltens2021]

5. Trial Design Implications

• Longer trial duration (116 weeks) did not compensate for insufficient amyloid clearance
• The cognitive reserve of enrolled patients may have masked treatment effects
• Sophisticated statistical approaches may be needed to detect modest effects[@cummings2023]

Comparison with Other Anti-Amyloid Therapies

| Feature | Gantenerumab (GRADUATE) | [Lecanemab](/therapeutics/lecanemab) (CLARITY) | [Donanemab](/therapeutics/donanemab) (TRAILBLAZER) |
|---------|------------------------|-----------------------------------------|------------------------------------------|
| Developer | Roche/Genentech | Eisai/Biogen | Eli Lilly |
| Administration | Subcutaneous | IV infusion | IV infusion |
| Dose | 510 mg q2w | 10 mg/kg q2w | 350 mg q4w |
| Amyloid reduction | ~50% | ~80% | ~70% |
| Amyloid-negative rate | 28% | 68% | 80% |
| CDR-SB benefit | Not significant | 0.45 (27%) p<0.001 | 0.70 (35%) p<0.001 |
| ARIA-E rate | 24.9% | 12.6% | ~24% |
| Trial duration | 116 weeks | 79 weeks | 76 weeks |
| Status | Discontinued | Approved (2023) | Approved (2024) |

Post-Trial Developments

Program Discontinuation

Roche discontinued gantenerumab development in January 2023 following the GRADUATE trial results[@roche2023]. However, the learnings from this program have informed the development of next-generation anti-amyloid therapies:

Trontinemab (RO7129511)

Roche's pipeline includes trontinemab, a brain-penetrant anti-Aβ antibody that may address the brain penetration limitations observed with gantenerumab. This program represents a direct application of lessons learned from the GRADUATE experience.

Broader Field Impact

The GRADUATE results have influenced the broader anti-amyloid field:

• Validated amyloid as a therapeutic target (biomarker engagement achieved)
• Informed dose selection for next-generation antibodies
• Highlighted importance of complete amyloid clearance
• Supported combination therapy approaches targeting both amyloid and tau[@musiek2023][@reim2023]

Future Directions

The gantenerumab program, while not successful clinically, has advanced our understanding of [Alzheimer's disease](/diseases/alzheimers-disease) pathophysiology and treatment:

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Amyloid-Beta](/proteins/amyloid-beta)
• [Lecanemab](/therapeutics/lecanemab)
• [Donanemab](/therapeutics/donanemab)
• [Anti-Amyloid Immunotherapy](/therapeutics/anti-amyloid-therapeutics)
• [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
• [Amyloid-Related Imaging Abnormalities (ARIA)](/entities/aria)
• [Clinical Trials in Alzheimer's Disease](/clinical-trials/overview)

External Links

• [ClinicalTrials.gov: GRADUATE I](https://clinicaltrials.gov/study/NCT03444870)
• [ClinicalTrials.gov: GRADUATE II](https://clinicaltrials.gov/study/NCT03443973)
• [Roche Clinical Trials](https://forpatients.roche.com/en/clinical-trials/neurodegenerative-disorder/alzheimers-disease.html)
• [Alzheimer's Prevention Initiative](https://alz.org/)

References